What does everyone make of this dot point
Seems like as a monotherapy it's not so effective as when it was given as dual, where the benefit was clinically significant 4 weeks following. Also the Cd in dual is ~40% higher.
Though I'm a little confused as the above states this group had less severe depression but it is unclear what the group of 31 patients receiving Xananmem as a monotherapy was (severe depression, less severe or mix)
Ann: ACW XanaCIDD phase 2a trial topline results, page-44
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.002(5.56%) |
Mkt cap ! $67.79M | |||
| Open | High | Low | Value | Volume |
| 2.8¢ | 2.8¢ | 2.5¢ | $432.5K | 16.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 7673891 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.6¢ | 643952 | 6 |
View Market Depth
| Last trade - 14.50pm 14/08/2024 (20 minute delay) ? |
| ACW (ASX) Chart |